AP PHarma as announced that it has received a Complete Response Letter (CRL) from the FDA regarding its New Drug...
Unmet patient needs in MS management
Patient case study discussions led by MS experts
ECF 2022
High-efficacy therapies
Containing relevant Learning Zones, guidelines, trials and news.
Watch MS patient case study discussion highlights from the MS Medical Grand Rounds meeting at MENACTRIMS 2022, chaired by Prof. Bassem Yamout.
Mavenclad (cladribine tablets) from Merck KGaA, is now indicated for the treatment of adult patients with relapsing forms of Multiple Sclerosis (MS) with active disease as defined by clinical or imaging features following approval by the MHRA, meaning more newly diagnosed patients could be eligible for treatment earlier in their disease course.
MediciNova, Inc.,announced its plans for a Phase III clinical trial of MN 166 (ibudilast) in progressive multiple sclerosis (progressive MS)...